Document:

exv4w4

EXHIBIT 4.4

RESTATED AND AMENDED ARTICLES OF INCORPORATION

OF

COEUR D’ALENE MINES CORPORATION

          Pursuant to the provisions of Section 30-1-1007 of the Idaho Business Corporation Act,
the undersigned corporation, pursuant to resolutions duly adopted by its board of directors and
shareholders, hereby adopts the following restated and amended articles of incorporation:

ARTICLE I

          That the name of said corporation shall be “COEUR D’ALENE MINES CORPORATION.”

ARTICLE II

                    (a) The corporation is authorized to issue two classes of shares of capital stock to
be designated, respectively, “common stock” and “preferred stock”. The total number of such shares
which the corporation shall have the authority to issue shall be 160 million. The total number of
shares of common stock authorized to be issued shall be 150 million shares, $0.01 par value per
share, and the total number of shares of preferred stock authorized to be issued shall be 10
million shares, $1.00 par value per share.

                    (b) The shares of preferred stock may be issued from time to time in one or more
series. The Board of Directors is hereby authorized to establish from time to time by resolution of
resolutions the number of shares to be included in each such series, and to fix the designation,
powers, preferences and relative participating, optional, conversion and other special rights of
the shares of each such series and the qualifications, limitations or restrictions thereof,
including but not limited to the fixing or alteration of the dividend rights, dividend rate or
rates, conversion rights, voting rights, rights and terms of redemption (including sinking fund
provisions), the redemption price or prices, and the liquidation preferences of any wholly unissued
series of shares of preferred stock, or any or all of them, all to the fullest extent now or
hereafter permitted by the Idaho Business Corporation Act; and to increase or decrease the
authorized number of shares of any series subsequent to the issue of shares of that series. In case
the number of shares of any series shall be so decreased, the shares constituting such decrease
shall resume the status which they had prior to the adoption of the resolution originally fixing
the number of shares of such series. No vote of the holders of the common stock or preferred stock
shall, unless otherwise provided in the resolutions adopted by the Board of Directors creating any
particular series of preferred stock, be a prerequisite to the issuance of any shares of any series
of the preferred stock authorized by and complying with the conditions of this Article.

                    (c) Holders of the corporation’s common stock shall have no preemptive rights to
acquire unissued or treasury shares or securities convertible into such shares of the corporation’s
capital stock or carrying a right to subscribe to or acquire shares. Holders of the corporation’s
preferred stock shall have no preemptive rights to acquire unissued or treasury shares of the
corporation’s capital stock or carrying a right to subscribe to acquire shares, except to the
extent provided

 

 

under the resolution or resolutions adopted by the Board of Directors, creating any particular
series of such preferred stock.

ARTICLE III

          The street address of the corporation’s registered office is 505 Front Avenue, Coeur
d’Alene, Idaho 83814 and the name of its registered agent at that address is Dennis E. Wheeler.

ARTICLE IV

          The name and address of each incorporator is Joseph R. Gunn of Spokane, Washington,
George Turner of Spokane, Washington, R.W. Nuzum of Spokane, Washington and Fred T. Fudge of
Kellogg, Idaho.

ARTICLE V

               Section 1. Vote Required for Certain Business Combinations

                         A. Higher Vote for Certain Business Combinations. In addition to any
affirmative vote required by law or these Articles of Incorporation, and except as otherwise
expressly provided in Section 2 of this Article V:

                                   (i) any merger or consolidation of the Company or any Subsidiary (as
hereinafter defined) with (a) any Interested Shareholder (as hereinafter defined) or (b) any other
corporation or other person (whether or not itself an Interested Shareholder) which is, or after
such merger or consolidation would be, an Affiliate (as hereinafter defined) of an Interested
Shareholder; or

                                   (ii) any sale, lease, exchange, mortgage, pledge, transfer or other
disposition (in one transaction or a series of transactions) to or with any Interested Shareholder
or any Affiliate of any Interested Shareholder of any assets of the Company or any Subsidiary (in
one transaction or a series of transactions) of any securities of the Company or any Subsidiary to
any Interested Shareholder or any Affiliate of any Interested Shareholder in exchange for cash,
securities or other property (or a combination thereof) having an aggregate Fair Market Value of
$20 million or more; or

                                   (iii) the issuance or transfer by the Company or any Subsidiary (in one
transaction or a series of transactions) of any securities of the Company or any Subsidiary to any
Interested Shareholder or any Affiliate of any Interested Shareholder in exchange for cash,
securities or other property (or a combination thereof) having an aggregate Fair Market Value of
$20 million or more; or

2

 

                                   (iv) the adoption of any plan or proposal for the liquidation or
dissolution of the Company proposed by or on behalf of an Interested Shareholder or any Affiliate
of any Interested Shareholder; or

                                   (v) any reclassification of securities (including any reverse stock
split), or recapitalization of the Company, or any merger or consolidation of the Company with any
of its Subsidiaries or any other transaction (whether or not with or into or otherwise involving an
Interested Shareholder) which has the effect, directly or indirectly, of increasing the
proportionate share of the outstanding shares of any class of equity or convertible securities of
the Company or any Subsidiary which is directly or indirectly owned by any Interested Shareholder
or any Affiliate of any Interested Shareholder;

shall require the affirmative vote of the holders of at least 80% of the shares of Common Stock of
the Company entitled to vote generally in the election of directors (the “Common Stock”). Such
affirmative vote shall be required notwithstanding the fact that no vote may be required, or that a
lesser percentage may be specified, by law or in any agreement.

                         B. Definition of “Business Combination”. The term “Business Combination” as
used in this Article V shall mean any transaction which is referred to in any one or more of
clauses (i) through (v) of paragraph A of this Section 1.

               Section 2. When Higher Vote is Not Required. The provisions of Section 1 of this
Article V shall not be applicable to any particular Business Combination, and such Business
Combination shall require only such affirmative vote as is required by law and any other provision
of these Articles of Incorporation, if all of the conditions specified in either of the following
paragraphs A and B are met:

                         A. Approval by Continuing Directors. The Business Corporation shall have been
approved by a majority of the Continuing Directors (as hereinafter defined).

                         B. Price and Procedure Requirements. All of the following conditions shall have
been met:

                                   (i) The aggregate amount of the cash and the Fair Market Value (as
hereinafter defined) as of the date of the consummation of the Business Combination of
consideration other than cash to be received per share by holders of Common Stock in such Business
Combination shall be at least equal to the higher of the following:

                                             (a) (if applicable) the highest per share price (including any
brokerage commissions, transfer taxes and soliciting dealers’ fees) paid by the Interested
Shareholder for any shares of Common Stock acquired by it (1) within the two-year period
immediately prior to the first public announcement of the proposal of the Business Combination (the
“Announcement Date”) or (2) in the transaction in which it became an Interested Shareholder,
whichever is higher; and

3

 

                                             (b) the Fair Market Value per share of Common Stock on the
Announcement Date or on the date on which the Interested Shareholder became an Interested
Shareholder (such latter date is referred to in this Article V as the “Determination Date”),
whichever is higher.

                                   (ii) The consideration to be received by holders of the Common Stock shall
be in cash or in the same form as the Interested Shareholder has previously paid for shares of such
Common Stock. If the Interested Shareholder has paid for shares of Common Stock with varying forms
of consideration, the form of consideration for such Common Stock shall be either cash or the form
used to acquire the largest number of shares of such Common Stock previously acquired by it.

                                   (iii) After such Interested Shareholder has become an Interested
Shareholder, such Interested Shareholder shall not have received the benefit, directly or
indirectly (except proportionately as a shareholder), of any loans, advances, guarantees, pledges
or other financial assistance or any tax credits or other tax advantages provided by the Company,
whether in anticipation of or in connection with such Business Combination or otherwise.

                                   (iv) A proxy or information statement describing the proposed Business
Combination and complying with the requirements of the Securities Exchange Act of 1934 and the
rules and regulations thereunder (or any subsequent provisions replacing such Act, rules or
regulations) shall be mailed to public shareholders of the Company at least 30 days prior to the
consummation of such Business Combination (whether or not such proxy or information statement is
required to be mailed pursuant to such Act or subsequent provisions).

               Section 3. Certain Definitions. For the purposes of this Article V:

                         A. A “person” shall mean any individual, firm, corporation or other entity.

                         B. “Interested Shareholder” shall mean any person (other than the Company or
any Subsidiary of the Company) which:

                                   (i) is the beneficial owner, directly or indirectly, of more than 10% of
the outstanding shares of the Company’s Common Stock; or

                                   (ii) is an Affiliate of the Company and at any time within the two-year
period immediately prior to the date in question was the beneficial owner, directly or indirectly,
of 10% or more of the then outstanding Common Stock; or

                                   (iii) is an assignee of or has otherwise succeeded to any shares of Common
Stock which were at any time within the two-year period immediately prior to the date in question
beneficially owned by any Interested Shareholder, if such assignment or succession shall have
occurred in the course of a transaction or series of transactions not involving a public offering
within the meaning of the Securities Act of 1933;

provided, however, that a person shall not be an Interested Shareholder if such person became the
beneficial owner of more than 10% of the Company’s Common Stock prior to April 3, 1985.

4

 

                         C. A person shall be a “beneficial owner” of any Common Stock:

                                   (i) which such person or any of its Affiliates or Associates (as
hereinafter defined) beneficially owns, directly or indirectly; or

                                  (ii) which such person or any of its Affiliates or Associates has (a) the
right to acquire (whether such right is exercisable immediately or only after the passage of time),
pursuant to any agreement, arrangement or understanding or upon the exercise of conversion rights,
exchange rights, warrants or options, or otherwise, or (b) the right to vote pursuant to any
agreement, arrangement or understanding; or

                                   (iii) which are beneficially owned, directly or indirectly, by any other
person with which such person or any of its Affiliates or Associates has any agreement, arrangement
or understanding or the purpose of acquiring, holding, voting or disposing of any shares of Common
Stock.

                         D. For the purpose of determining whether a person is an Interested Shareholder
pursuant to paragraph B of this Section 3, the number of shares of Common Stock deemed to be
outstanding shall include shares deemed owned through application of paragraph C of this Section 3
but shall not include any other shares of Common Stock which may be issuable pursuant to any
agreement, arrangement or understanding, or upon exercise of conversion rights, warrants or
options, or otherwise.

                         E. “Affiliate” or “Associate” shall have the respective meanings ascribed to
such terms in Rule 12b-2 of the General Rules and Regulations under the Securities Exchange Act of
1934, as in effect on April 3, 1985.

                         F. “Subsidiary” means any corporation of which a majority of any class of
equity security is owned, directly or indirectly, by the Company, provided, however, that for the
purposes of the definition of Interested Shareholder, set forth in paragraph B of this Section 3,
the term “Subsidiary” shall mean only a corporation of which a majority of each class of equity
security is owned, directly or indirectly, by the Company.

                         G. “Continuing Director” means any member of the Board of Directors of the
Company (the “Board”) who is unaffiliated with the Interested Shareholder and was a member of the
Board prior to the time that the Interested Shareholder became an Interested Shareholder, and any
successor of a Continuing Director who is unaffiliated with the Interested Shareholder and is
recommended to succeed a Continuing Director by the majority of Continuing Directors than on the
Board.

                        H. “Fair Market Value” means: (i) in the case of stock, the highest closing sale
price during the 30-day period immediately preceding the date in question of a share of such stock
on the Composite Tape for New York Stock Exchange Listed Stocks, or, if such stock is not quoted on
the Composite Tape, on the New York Stock Exchange, or, if such stock is not listed on such
Exchange, on the principal United States securities exchange registered under the Securities
Exchange Act of 1934 on which such stock is listed, or, if such stock is not listed on any such

5

 

exchange, the highest closing bid quotation with respect to a share of such stock during the 30-day
period preceding the date in question on the National Association of Securities Dealers, Inc.
Automated Quotations System or any system then in use, or if no such quotations are available, the
fair market value on the date in question of a share of such stock as determined by the Board in
good faith; and (ii) in the case of property other than cash or stock, the fair market value of
such property on the date in question as determined by the Board in good faith.

                             I. In the event of any Business Combination in which the Company survives, the
phrase “other consideration to be received” as used in paragraph B(i) of Section 2 of this
Article V shall include the shares of Common Stock retained by the holders of such shares.

                    Section 4. Powers of the Board of Directors. A majority of the directors of the
Company shall have the power and duty to determine for the purposes of this Article V, on the basis
of information known to it after reasonable inquiry, (A) whether a person is an Interested
Shareholder, (B) the number of shares of Common Stock beneficially owned by any person, (C) whether
a person is an Affiliate or Associate of another and (D) whether the assets which are the subject
of any Business Combination have, or the consideration to be received for the issuance or transfer
of securities by the Company or any Subsidiary in any Business Combination has, an aggregate Fair
Market Value of $20 million or more. Any such determination made in good faith shall be binding and
conclusive on all parties.

                    Section 5. No Effect on Fiduciary Obligations of Interested Shareholders. Nothing
contained in this Article V shall be construed to relieve any Interested Shareholder from any
fiduciary obligation imposed by law.

                    Section 6. Amendment, Repeal, etc. Notwithstanding any other provision of or the
By-Laws of the Company (and notwithstanding the fact that a lesser percentage may be specified by
law, these Articles of Incorporation or the By-Laws of the Company), the affirmative vote of the
holders of 80% or more of the outstanding shares of the Company’s Common Stock shall be required to
amend or repeal, or adopt any provisions inconsistent with this Article V.

ARTICLE VI

          The personal liability of a director of the corporation to the corporation or its
shareholders for money damages for any action taken, or any failure to take any action, as a
director, shall be eliminated; provided, however, that the liability of a director shall not be
eliminated for (i) the amount of a financial benefit received by a director to which he is not
entitled, (ii) an intentional infliction of harm on the corporation or the shareholders, (iii) a
violation of Section 30-1-833 of the Idaho Business Corporation Act, or (iv) an intentional
violation of criminal law.

ARTICLE VII

          The corporation shall be obligated to indemnify any individual who is a party to a
proceeding because he is a director of the corporation against liability to any person for action
taken, or any

6

 

failure to take any action, as a director, and expenses incurred in the proceeding to the fullest
extent provided by law in accordance with Section 30-1-851(1)(b) of the Idaho Business Corporation
Act, except liability for (i) receipt of a financial benefit to which he is not entitled, (ii) an
intentional infliction of harm on the corporation or its shareholders, (iii) a violation of
Section 30-1-833 of the Idaho Business Corporation Act, or (iv) an intentional violation of
criminal law.

          The foregoing Restated and Amended Articles of Incorporation, which include amendments to
the Articles of Incorporation, correctly set forth the provisions of the Articles of Incorporation
as heretofore and hereby amended, and supersede the original Articles of Incorporation and all
previous amendments thereto.

7exv10w1

Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A
complete version of this exhibit has been filed separately with the Securities and Exchange
Commission.

SUPPLY CONTRACT

dated as of January 3. 2006 by and among

Eurand S.p.A., a company incorporated under the laws of Italy, with offices at Via Martin Luther
King, 13, 20060 Pessano con Bornago — Milan, Italy (hereafter called Customer)

and

Nordmark Arzneimittel GmbH & Co., a company incorporated under the laws of Germany, with offices at
Pinnaualle, 4 25436 Uetersen — Germany (hereafter called Supplier)

(each a “Party” and Eurand and Nordmark, the “Parties”).

 

 

PREAMBLE

	A.	 	Whereas, Customer manufactures drug products containing Pancreatin *** (hereafter called the
Drug Product);
	 
	B.	 	Whereas, Customer is also planning to apply in its own name for a Marketing Authorization for
the Drug Product in the USA, Europe and any other markets and — upon registration — to
distribute directly or indirectly the Drug Product in the USA, Europe and any other markets;
and wishes to be supplied by Supplier with Pancreatin of a specified quality, as defined in
Article 1 and;
	 
	C.	 	Whereas, Supplier manufactures APIs and drug products and is the holder of the manufacturing
authorizations issued by the competent authorities.
	 
	D.	 	Whereas, Supplier wishes to supply Customer with Pancreatin.

NOW THEREFORE, the Parties agree the following terms and conditions for the supply of Pancreatin.

DEFINITIONS

Affiliate means a company or other entity or organization or person that owns or controls, is owned
or controlled by or is under common ownership or control with another company or other entity or
organization or person.

API means Active Pharmaceutical Ingredient.

cGMP means current Good Manufacturing Practice as defined in the guidelines Part II (Basic
Requirements for Active Substances used as Starting Materials) of the “The Rules Governing
Medicinal Products in the European Union” (Volume 4, EU Guidelines to Good Manufacturing Practice
Medicinal Products for Human and Veterinary Use) and the FDA Guidance for Industry Q7A (Good
Manufacturing Practice Guidance for Active Pharmaceutical Ingredients).

Contract is this agreement for the non-exclusive supply by Nordmark to Eurand of the Contracted
Product.

Costs means any cost or expense, including reasonable attorneys’ fees and costs of investigating
and defending against lawsuits, complaints, actions or other pending or threatened litigation.

Current Supply Agreement means the agreement signed between the Parties *** and ***.

Delivery Date means the date set forth in the Orders with which Customer requests Supplier to
deliver Contracted Product to Customer’s warehouse.

Drug Product means drug products *** Pancreatin ***.

2

 

Lead Time means the time mutually agreed upon (as specified in Appendix 3) for each
individual Contracted Product, in advance of any requested Delivery Date, by which an Order must be
placed by Customer for Supplier to be obligated to deliver by the Delivery Date under this
Contract.

Marketing Authorization means any approvals, authorizations, licenses or registrations from a
relevant health authority for the distribution, promotion, marketing and sale of a drug product.

Order means the written purchase orders by fax or by e-mail placed by Customer to Supplier as
defined in Article 3.2.

Quality Agreement (attached to this Contract as Appendix 4) means the agreement between
Supplier and Customer defining the roles and responsibilities of the Supplier’s Quality Department
when providing services for Customer. This agreement also defines how the Supplier’s and Customer’s
Quality Departments will interact with each other.

Recall means any action to recover title or possession or halt distribution, prescription, or
consumption of Contracted Product or Drug Product sold or shipped to third parties. The term
“Recall” also applies to Contracted Product or Drug Product due to non-conformities identified in
the Contracted Product that would have been subject to recall if it had been shipped.

Regulatory Authorities means the US FDA, the European authorities (the EMEA and competent authority
of each single EU member state), and any other regulatory authority where a request for Marketing
Authorization of a drug product containing the Contracted Product has been or will be filed or
Marketing Authorization has been or will be obtained.

Service Level means the level of service that the Supplier guarantees to the Customer according to
Article 3.5.

Article 1

Subject of the Contract

1.1 This Contract is for the *** purchase by Customer from Supplier and the *** sale by Supplier to
Customer of the *** Pancreatin (hereafter called the Contracted Product) as set out in the
Specifications attached to this Contract as Appendix 1 (the Specifications). The
Specifications also include the different Customer codes of the Contracted Product.

1.2 Customer undertakes to purchase from Supplier at least *** of the Contracted Product having
Customer codes *** (or any future code relating to the *** and ***. Supplier undertakes to supply
Customer with up to 100% of Customer’s total requirements of the Contracted Product, if *** by
Customer. Given the strategic importance of the Drug Product for Customer, it is Customer’s
intention and strategy not to be dependent on one supply source, but to have alternative suppliers
of the Contracted Product.

1.3 Supplier recognizes the right of the Customer to purchase up to 100% of all its requirements of
the Contracted Product from other suppliers (the Customer being thereby released from its
obligations under Article 1.2) should Supplier be unable to *** Customer with the Contracted
Product both in terms of *** and ***. However, Customer shall use its reasonable commercial efforts
to reinstate its obligation under Article 1.2 as soon as Supplier is once again able to supply the
Contracted Product to Customer in accordance with the *** *** requirements of this Contract.
Subject to Article 8 Supplier shall indemnify Customer for any amount paid to the

3

 

*** exceeding the agreed upon price. Such indemnity will not apply to the first Order that Supplier
has been *** in accordance with this Contract.

1.4 Customer shall be entitled to modify the Specifications at any time in the event that such
modification is necessary or expedient based upon regulatory requirements. In any other
circumstances, Customer may modify the Specifications with the *** of ***, which *** shall not be
***. In the event that such modifications have a significant impact on the *** of the Contracted
Product or the ***, the Parties shall negotiate in good faith to amend this Contract to reflect the
new *** and/or ***.

The Customer’s share of costs for modifying the Specifications shall be established by the Parties
taking into account (a) the possibility for the Supplier to also *** with its *** customers and (b)
that *** shall *** be responsible for the entire or a *** share of such cost.

The Supplier undertakes to timely modify the Specifications even if the negotiations between the
Parties regarding the new *** and *** are still pending.

If the Parties ***, in good faith, agree upon a *** and/or *** for the modified products within
three months of the date of the Customer’s or competent authority’s written *** for a *** of the
Specifications, then the Contract will remain in force but Customer shall be released from its
obligations under Article ***.

1.5 Any new agreed upon ***, or new Pancreatin *** with the agreed upon prices, will automatically
be an integral part of the Contract and included in Appendix 1 — “Specifications of the
Contracted Product” and Appendix 2 — “Determination of the Prices”.

Article 2

Supply

2.1 Supplier undertakes to supply the requirements of Customer for the Contracted Product in
accordance with Articles *** and *** for the term of the Contract as set out in Article 9. Under no
circumstance shall Supplier *** or otherwise *** its obligations under this Contract to any ***,
including any ***, without the prior written approval of Customer.

2.2 Any (previously authorized) *** executed by Supplier in connection herewith shall be fully
consistent with the provisions of this Contract and any relevant Sale/Purchase Contract, including
Customer’s right of *** to any of the sub-contractors’ ***.

2.3 Supplier shall be and remain in any case fully and solely responsible for any *** or any *** in
the performance of this Contract or any Sale/Purchase Contract, even when directly or indirectly
attributable to the responsibility of any of its sub-contractors.

Article 3

Forecast and orders

3.1 Exclusively in order to facilitate Supplier in carrying out production planning appropriately,
Customer will provide Supplier with a non-binding estimate of Customer’s annual requirements for
the Contracted Product for each calendar year by September 30th of the previous calendar
year. A more detailed non-binding forecast shall be given by Customer to Supplier by October 31st
of each calendar year, setting out the anticipated quantities on a month by month

4

 

basis. Such forecast shall be updated quarterly by Customer, and sent to Supplier two months before
the end of the calendar quarter prior to the calendar quarter to which such estimate relates. None
of such estimates however will constitute a binding order by the Customer. The sole document which
shall be binding upon the Customer, shall be any purchase order issued pursuant to Articles 3.2 and
3.3.

3.2 Customer will place firm written purchase orders by fax or by e-mail (hereafter “Order”) with
Supplier for the Contracted Product, specifying the quantity and the Customer Code of the ordered
Contracted Product, no later than the designated Lead Time (as foreseen in Appendix 3) before the
required Delivery Date. The Delivery Date set out in the Order is the date upon which delivery is
to be made to the Customer’s warehouse. Supplier shall deliver the Contracted Product so ordered on
the Delivery Date, or not earlier or not later than *** working *** with respect to the Delivery
Date designated on the applicable Order unless otherwise provided below. Supplier will acknowledge
receipt of the Order by sending an Order confirmation to Customer by fax or e-mail within one (1)
week of receipt of the Order. However, such confirmation to Customer shall be required for
information purposes only since the receipt by Supplier of an Order (provided that it is in
accordance with the provisions of this Contract) shall entail the immediate and automatic execution
of a sale/purchase contract for the relevant ordered Contracted Product (each, a Sale/Purchase
Contract) which shall be governed by this Contract and the specific provisions of the Order.

3.3 Customer will be entitled to place Orders for amounts exceeding the quarterly estimated
quantities as set out in Article 3.1 above. In such case, the Supplier shall be obligated to
fulfill such Orders up to a maximum of *** percent) above such quarterly estimate in accordance
with the terms of this Contract, as set out in Article 3.2. For any quantities ordered in excess of
*** of the quarterly estimate, Supplier will use its reasonable commercial efforts to supply these
additional requirements as close to the specified Delivery Date as possible and will inform
Customer within *** of receiving the Order on which date such additional quantities of Contracted
Product (i.e. in excess of ***) will be delivered. Notwithstanding the above, Supplier shall supply
the excess quantity no later than the beginning of the immediately following calendar quarter
provided that there is not less than *** weeks until that date. Customer however has the right to
cancel the Order and order the relevant Contracted Product from another supplier if such a delay is
not acceptable and must inform the Supplier of such cancellation immediately.

3.4 Independently of that which is provided for in Art. 3.3, Supplier shall continuously keep a
security stock free of charge for each Customer code of the Contracted Product, of a total quantity
that corresponds to the average *** foreseen for a period of *** months as determined in the
Customer’s *** applicable from time to time, in order to satisfy both unforeseen and urgent
requests from Customer and to be able to supply ordered Contractual Product should Supplier have
any production problems for whatever reason.

Should the Drug Product only be allowed by the FDA to be manufactured with Contracted Product only
*** from ***, the Supplier undertakes to execute long term supply contracts with *** of *** in
order to ensure the availability of *** to manufacture the Contracted Product.

3.5 With the exception of *** events pursuant to Article ***, Supplier guarantees the following
service level (hereinafter called the Service Level):

(a) Subject to the *** of any Contracted Products subject of Orders received from Customer in any
calendar year shall be delivered no later than the required Delivery Date. In the event that any
Order contains requirements for more than one code of the Contracted Product, Supplier shall be
obliged to supply by the required Delivery Date a minimum of *** of each ordered code.

5

 

(b) Subject to Articles ***, the delivery of all other Contracted Product subject of Orders (i.e.
the remaining ***) which are not delivered by the required Delivery Date, shall be delivered by no
more than *** weeks from the required Delivery Date. In such a case, Customer will be notified as
soon as possible in writing by Supplier of the *** of delivery of such delayed Contracted Product.

(c) In the event that any portion of any lot of delivered Contracted Product is incomplete or does
not meet the Specifications, the entire lot will be considered *** and not to have been delivered
by the Delivery Date, provided that the *** in the lot is due to the fault of Supplier.

Should the Service Level not be met in relation to any *** period (from *** to *** of each year),
Customer shall be released from its purchase obligations under Article 1.2 in the following ***. If
the Service Level is achieved in such following contractual year, the original purchase obligation
as foreseen in Article 1.2 shall be reinstated starting from the subsequent year (e.g. Service
Level not met during 2008, then Customer is released from its purchase obligations under Article
1.2 in 2009. If during 2009 the Service Level is met, the original purchase obligation as foreseen
in Article 1.2 shall be reinstated starting from 2010).

Article 4

Conditions of supply

4.1 Deliveries of the Contracted Product shall be at *** as indicated in the relevant Order (***,
all costs included).

4.2 Without prejudice to Article 5, Supplier shall enclose in each lot of delivered Contracted
Product (Supplier will use reasonable commercial efforts in good faith to *** the minimum number of
lots to fulfill Orders where the minimum lot shall be not less than ***) a certificate of
compliance stating that the Contracted Product meets the Specifications. The minimum quantity of
Contracted Product per Order shall be ***. The Contracted Product delivered by Supplier shall have
at least *** of *** or retest period, as set out in the certificate of analysis referred to in
Article 4.3 (for example, if the retest period is ***, Customer will not accept batches of
Contracted Product that are due to be retested earlier than *** months from their delivery).

4.3 Supplier shall perform all the *** and *** quality control tests and quality assurance reviews
on the Contracted Product as are required by the Supplier’s last DMF (Drug Master File) for the ***
control tests and the Specifications for the *** tests, and shall certify in writing to Customer
that each batch of the Contracted Product delivered to Customer was manufactured in conformity
therewith and that the Contracted Product contained in each shipment complies with the
Specifications, and the other terms and conditions of this Contract. All deliveries of Contracted
Product by Supplier shall be accompanied by all appropriate documentation required under applicable
laws in order for Customer to offer the Contracted Product for sale, including (i) a certificate of
analysis as provided for by the cGMP and (ii) a *** or quality control certification that the
Contracted Product supplied hereunder has been manufactured in conformity with cGMPs and other
applicable regulations, which will be added to the certificate of analysis form by Supplier.

4.4 Customer undertakes that it shall inspect each lot of the delivered Contracted Product promptly
upon receipt at Customer’s plant, to verify that the lot is complete and was not damaged in
shipment and will promptly inform Supplier of any non-compliance. Customer will subsequently test
the Contracted Product in accordance with the Specifications. Supplier shall keep “***” samples of
Contracted Product under proper storage conditions as specified in *** (***) and will be
responsible
for all *** testing of the Contracted Product, as required to meet *** requirements (as they may be
amended from time to time).

6

 

4.5 In the event of *** the Specifications or shortages being found during the Customer’s tests as
provided for in Article 4.4, Customer shall send a report to Supplier as soon as possible and in
any event within *** weeks of receipt of the Contracted Product at Customer’s warehouse. Should
Supplier and Customer agree that the claim is ***, Supplier undertakes to supply Customer free of
charge and as soon as possible (but in any event not later than *** *** at Customer’s warehouse
from the date of the notice of claim) with a *** quantity of the Contracted Product. Supplier shall
also reimburse to Customer all *** costs and expenses incurred by it arising out of or in
connection with the *** of the Contracted Product delivered by Supplier.

Any dispute arising between Customer and Supplier concerning the *** of any delivery of
Contracted Product with the Specifications which cannot be settled between the two Parties, shall
be submitted to an independent expert appointed by both Parties and the relevant cost will be
borne by the Party ***.

The decision of said expert shall be binding on Supplier and Customer. However, in the event of
dispute and whilst awaiting the decision ***, Supplier undertakes to supply Customer as soon as
possible, but in any event not later than *** weeks at Customer’s warehouse from the date of the
notice of claim, with a replacement quantity of the Contracted Product.

The charges, including the fees and expenses of the expert, relating to any dispute described in
this paragraph shall be paid by *** if the expert declares the delivery *** conformity with the
Specifications and/or the relevant Order and by *** if the expert declares the delivery to be ***
with the *** and/or the relevant Order. The sole remedy for shortages of the Contracted Product or
the rejection of Contracted Product that does not *** shall be Supplier’s *** Contracted Product as
soon as possible and *** in accordance with *** Article ***.

4.6 Upon request of Customer, Supplier agrees to provide Customer with the documentation described
in the Quality Agreement.

4.7 The execution by Customer of any *** or ***, as well as of any other document released upon any
*** and *** made at any time on the Contracted Product shall not discharge Supplier from any of its
obligations and liabilities under Article 5 “Warranties”, or from any liability or responsibility
deriving from the existence or the subsequent arising out or discovery of any ***, *** or ***
affecting the Contracted Product.

Article 5

Warranties

5.1 Without prejudice to its obligations to supply Customer with up to *** of Customer’s total ***
of the Contracted Product, if requested by Customer. Supplier warrants a *** capacity of up to ***
Should Customer require quantities exceeding the ***, the Parties will make specific agreements in
good faith to meet Customer’s ***.

5.2 Supplier warrants to have all the authorizations, licenses and permits necessary to carry out
the activities contemplated by this Contract and, generally, to perform all its obligations
provided for hereunder and that it shall operate in full compliance with the laws and regulations
applicable

7

 

from time to time, also in the future, in relation to this Contract. Without prejudice to the
generality of the foregoing, Supplier undertakes to seek to *** from the ***, *** as an API
manufacturer for the USA, Europe and other markets, to pass any regulatory inspection and
undertakes to continuously satisfy all the relevant necessary regulatory requirements and maintain
a *** to the cGMP regulations (FDA, EU and other markets) for the purposes of maintaining such
regulatory approval.

5.3 Supplier warrants that the Contracted Product shall, when delivered to Customer, be free from
defects of any kind (including materials, workmanship and manufacturing process) and comply with
the Specifications.***

5.4 Supplier warrants that the Contracted Product shall be produced in a facility and in a manner
compliant with current *** and *** and all other applicable laws and in accordance with the Quality
Agreement. Furthermore, Supplier warrants that its personnel that will carry out the activities
contemplated by this Contract shall have the necessary qualifications, skills and organisation to
correctly perform such activities and will not need to sub-contract any of them. Supplier also
warrants the availability of the necessary number of its personnel to duly carry out such
activities. Supplier also represents and warrants that it complies and shall comply with all laws
and regulations applicable from time to time, also in the future.

5.5 Supplier further warrants that upon delivery to Customer‘s warehouse the Contracted Product
will not have been adulterated or misbranded in any way.

5.6 Supplier warrants that the Contracted Product worldwide will not infringe or violate any patent
or other industrial or intellectual property right of any third party.

5.7 Supplier’s warranty obligations under this Article 5 shall continue as to each delivered
Contracted Product for a period of *** from its delivery to Customer.

5.8 Each Party represents that it has maintained and shall maintain during the term of this
Contract, as well as *** after termination of this Contract, sufficient product liability
insurance, with appropriate policy limits, to cover the risks associated with the performance of
its obligations under this Contract, but in any event each Party shall maintain pharmaceutical
product liability insurance with limits not less than *** and *** in the aggregate for *** and ***
damage. Each Party agrees to provide the other Party with copies of certificates of insurance, when
applicable, upon request as written evidence of such coverage.

5.9 Supplier will maintain appropriate records to enable the immediate identification of any *** of
the Contracted Product delivered to Customer.

Article 6

Delivery price

6.1 The price of the Contracted Product and the rules that *** are specified in Appendix 2
of this Contract.

8

 

Article 7

Payment conditions

7.1 The *** for the Contracted Product shall be paid within *** days from the date of the
Supplier’s invoice, which shall be issued by the Supplier not earlier than the date of shipment of
the relevant Contracted Product.

7.2 Customer shall be entitled to *** (if it is the case also on a provisional basis) any amount
due to Supplier hereunder (and at any rate suspend the relevant payment pursuant to Article 1460 of
the Italian Civil Code) *** any amount which is or may become *** by Supplier to Customer under
this Contract.

Article 8

Force Majeure

8.1 Each of the Parties shall be excused from the performance or delay in performance of its
obligations under this Contract in the event such performance is prevented by Force Majeure (as
defined in the next sentence) and such performance shall be excused as long as the condition
constituting such Force Majeure continues plus an additional *** after termination of such
condition; provided, that the non-performing Party shall provide prompt notice to the other Party
of the particulars of the occurrence constituting Force Majeure and of its cessation and the
non-performing Party uses commercially reasonable efforts to remove the hindrance and to fulfill
its obligations. Force Majeure shall mean any cause or causes which wholly or partially prevent or
delay the performance of obligations arising under this Contract and which are not reasonably
within the control of the non-performing Party, including Acts of God, government regulations,
labor disputes (only at ***), floods, fires, ***, embargoes, *** of ***, or any delays in
transportation or detention by customs, health or other government authorities.

Article 9

Duration of contract — Termination

9.1 This Contract shall come into force (the Effective Date) from the date of the *** grant of the
*** in the *** and will expire on the *** anniversary of such date, unless earlier terminated as
set forth in Article 9.2. It is hereby agreed that *** year before the expiration date the Parties
shall meet to discuss and negotiate the possible extension or renewal of this Contract. The Parties
recognize that the date of registration and the subsequent Drug Product launch very much depend on
the collaboration between the Parties and the preparation by both Parties of the data to be
provided to the FDA. The Customer foresees the date of registration as taking place by ***.

9.2 An event of default under this Contract shall be deemed to exist upon the occurrence of any one
or more of the following events:

(a) failure by Supplier to correctly and fully perform any of its obligations under Articles ***
*** and ***.

(b) failure by Customer to *** and fully perform any of its obligations under Articles ***.

9

 

(c) failure by either Party hereto to perform fully any *** provision of this Contract and such
breach continues (i) for a period of *** days after notice of such non-performance or (ii) if the
non-performing Party shall commence within such *** days and shall thereafter proceed with all due
diligence to cure such failure and such failure is not cured within such longer period (not to
exceed ***) as shall be reasonably necessary for such Party to cure the same with all due
diligence;

(d) either Party liquidates its business; there is a request to appoint a receiver, administrator
or similar officer over any of such Party’s assets or business; a Party makes an arrangement for
the benefit of its creditors; or a Party goes into liquidation or is submitted to any other
insolvency procedure.

9.3 Upon the occurrence and during the continuation of any event of default hereunder, the Party
not in default shall have the right, at its option, to terminate this Contract in whole or
terminate only the Sale/Purchase Contract affected by the event of default and to pursue any other
remedies provided under this Contract or now or hereafter existing under the applicable law.

Article 10

Recall

10.1 In the event of an actual or threatened Recall of the Drug Product required *** by a
governmental agency or authority of competent jurisdiction, or if a Recall is *** by either Party,
or jointly *** by both Parties, such Recall shall be promptly implemented and administered by ***
in a manner which is appropriate and reasonable under the circumstances and in conformity with
accepted trade practices. The Costs of any such Recall shall be borne by *** whose *** *** the
Recall to be necessary. Supplier shall have no obligation to *** of a Recall to the extent such
Recall is (a) caused by *** occurring after such *** is sold by ***; (b) due to *** or *** defects
for which *** has *** responsibility; or (c) due to any other *** by Customer of its duties under
this Contract, unless such Recall is due to a *** by both Supplier and Customer of their *** under
this Contract.

10.2 If any of Supplier, Customer or any governmental authority having jurisdiction *** or *** a
Recall due to a *** in the manufacture, processing, packaging or labeling of the Contracted
Product or Drug Product caused in whole or in part by *** (a Recall Defect), the most diligent
Party shall immediately notify the other Party thereof. Prior to commencing any Recall,
Customer shall *** with Supplier the *** for a Recall, and if such Recall is the *** of
Supplier as a result of a *** caused by *** the proposed manner in which Customer shall
conduct the Recall. If the Recall is *** in whole or in part by ***, Supplier shall assist ***
in the Recall in the manner agreed upon in as *** a manner as possible and in such a way as to
cause the least disruption to business, and to preserve the goodwill and reputation of their
respective customers.*** 10.3 With respect to any Recall caused by the negligence, mistake,
fault, error or omission of Supplier, its Affiliates, or subcontractors (including any
adulteration or misbranding of the Contracted Product by Supplier, or any introduction of the
Contracted Product into commerce in violation of any applicable rule, statute, regulation or
governmental requirement by Supplier), with respect to any Recall resulting from a Recall
Defect caused by Supplier, Supplier shall:*** (i) reimburse Customer and its Affiliates for
any and all *** directly incurred by Customer or its Affiliates in connection with the Recall;
and*** (ii) indemnify, save and hold Customer and its Affiliates harmless from and against any
and all *** to or *** by *** associated with or *** from any such Recall.

10

 

10.4 With respect to any Recall caused by the negligence, mistake, fault, error or omission of
Customer or its Affiliates (including any adulteration or misbranding of the Contracted Product by
Customer, or any introduction of the Drug Product into commerce in violation of any applicable
rule, statute, regulation or governmental requirement by Customer), Customer shall:

	***	 	(i) reimburse Supplier and its Affiliates and subcontractors for any and all *** directly
incurred by Supplier in connection with the Recall; and

	(ii)	 	indemnify, save and hold Supplier and its Affiliates and subcontractors harmless from and
against any and all *** to or *** by *** associated with or *** from any such Recall.

10.5 With respect to any Recall caused by the shared negligence, mistake, fault, error, or omission
of Supplier and Customer or their Affiliates or subcontractors, the Parties shall *** the *** and
*** of the Recall in the *** of their ***, mistake, fault, error or omission, and they shall
indemnify one another and their Affiliates and subcontractors with respect to third party claims
associated with or resulting from the Recall in the same proportion.

Article 11

Indemnification

11.1 Supplier shall indemnify, defend and hold harmless Customer and its Affiliates, and their
respective officers, directors and employees from any liability (including liability for death or
injury), damage, deficiency, loss, judgments, assessments and, Costs arising from or attributable
to: (a) Supplier’s negligent acts or omissions, willful wrongful acts or breach of any of its
representations, warranties, covenants or other obligations hereunder, or (b) product liability
claims including personal injury and death resulting from the manufacture, use, or sale of the
Contracted Product to the extent attributable to the responsibility of Supplier. The
indemnification is to be limited as follows: *** per claim per year and up to a *** per year,
including liability for death or injury.

11.2 Customer shall indemnify, defend and hold harmless Supplier and its Affiliates, its officers,
directors and employees from Costs directly or indirectly arising from or attributable to: (a)
Customer’s negligent acts or omissions, willful wrongful acts, breach of any of its
representations, warranties, covenants or other obligations hereunder, or (b) product liability
claims including personal injury and death resulting from the manufacture, use, or sale of the
Contracted Product to the extent attributable to the responsibility of Customer. The
indemnification is to be limited as follows: *** per claim per year and up to a *** per year,
including liability for death or injury.

11.3 Promptly after the receipt by any Party entitled to indemnity hereunder of (i) any claim or
(ii) the commencement of any action or proceeding, such person (the Aggrieved Party) will, if a
claim with respect thereto is to be made against any Party obligated to provide indemnification
pursuant to this Article 11 (the Indemnifying Party), give such Indemnifying Party written notice
of such claim or the commencement of such action or proceeding and shall permit the Indemnifying
Party to assume the defense of any such claim or any litigation resulting from such claim, and,
upon such assumption, shall reasonably cooperate with the Indemnifying Party in the conduct of such
defense. Failure by the Indemnifying Party to notify in writing the Aggrieved Party of its election
to defend any such action within a reasonable time, but in no event more than fifteen (15) days
after notice thereof shall have been given to the Indemnifying Party, shall be deemed a waiver by
the Indemnifying Party of its right to defend such action. If the Indemnifying Party assumes the
defense of any such claim or litigation resulting therefrom, the obligations of the Indemnifying
Party as to

11

 

such claim shall be limited to taking all steps necessary in the defense or settlement of such
claim or litigation resulting therefrom. The Aggrieved Party may participate, ***, in the defense
of such claim or litigation provided that the Indemnifying Party shall direct and control the
defense of such claim or litigation. The Indemnifying Party shall not, in the defense of such claim
or any litigation resulting therefrom, consent to entry of any judgment, except with the written
consent of the Aggrieved Party (which shall not be unreasonably delayed or withheld), or enter into
any settlement, except with the written consent of the Aggrieved Party (which shall not be
unreasonably delayed or withheld), which does not include as an unconditional term thereof the
giving by the claimant or the plaintiff to the Aggrieved Party of a release from all liability in
respect of such claim or litigation. In addition, all awards and costs payable by a third party to
the Aggrieved Party or the Indemnifying Party shall belong to the Indemnifying Party.

11.4 If the Indemnifying Party shall not assume the defense of any such claim or litigation
resulting therefrom, the Aggrieved Party may defend against such claim or litigation in such manner
as it may deem appropriate and, unless the Indemnifying Party shall deposit with the Aggrieved
Party a sum equivalent to the total amount demanded in such claim or litigation, or shall deliver
to the Aggrieved Party a surety bond in form and substance reasonably satisfactory to the Aggrieved
Party in such amount, the Aggrieved Party may settle such claim or litigation on such terms as it
may deem appropriate, and the Indemnifying Party shall promptly reimburse the Aggrieved Party for
the amount of all expenses, legal or otherwise, incurred by the Aggrieved Party in connection with
the defense against or settlement of such claim or litigation. If no settlement of such claim or
litigation is made, the Indemnifying Party shall promptly reimburse the Aggrieved Party for the
amount of any judgment rendered with respect to such claim or in such litigation and of all
expenses, legal or otherwise, incurred by the Aggrieved Party in the defense against such claim or
litigation.

11.5 The indemnification provided in this Article 11, subject to the limitations set forth herein,
shall be the exclusive remedy for damages available to any Aggrieved Party and shall survive
indefinitely the expiration or termination of this Contract.

Article 12

Final Clauses

12.1 Supplier shall give Customer prompt notice of any governmental audit of Supplier as it relates
to the manufacture, production or testing of the Contracted Product. Further, Supplier shall
provide Customer with any relevant documentation provided to it relating to any such audit.
Customer shall have the right to audit and inspect the manufacturing facility of Supplier provided
that such audit visits occur no more than *** each calendar *** per *** and that Customer gives
Supplier notice of a minimum of *** or as otherwise agreed to by the Parties prior to such visits,
unless quality problems arise of such seriousness as to justify an *** visit.

12.2 Supplier and Customer shall keep the other fully informed in writing of any notification or
other information, whether received directly or indirectly, that might (i) affect the
marketability, safety or effectiveness of any Drug Product, (ii) result in liability issues or
otherwise necessitate action on the part of either Party or (iii) result in Recall or seizure of
any Contracted Product or Drug Product.

12

 

12.3 Supplier shall promptly comply with all FDA and other Regulatory Authority’s filing and
reporting requirements with respect to the Contracted Product. Supplier shall be responsible for
*** that may be required during the registration process.

12.4 In the event that it is not possible to obtain registration of the Drug Product from the FDA
or other health authority by 31st December 2010, other than for either Party’s default,
both Parties will be entitled to terminate this Contract for convenience and no compensation,
indemnification, or other payment shall be due by either Party to the other in connection with such
termination.

12.5 This Contract and any and all information provided by one Party to the other pursuant to this
Contract (including all information relating to duration and quantity and price of the Contracted
Product) shall be deemed to be confidential information (Confidential Information). Each Party will
hold Confidential Information in complete confidence and will not, without the prior written
consent of the other, use or disclose it in whole or in part to any person other than to those who
are directly concerned with this Contract. The term “Confidential Information” shall not include
information:

	(i)	 	which at the time of disclosure to the other is in the public domain;
	 
	(ii)	 	which after disclosure becomes generally available to third parties from a source other than
the disclosing Party: provided that such source is not bound by a confidentiality or other
similar agreement with the discloser or by any other legal contractual or fiduciary obligation
which prohibits the disclosure of such Confidential Information;
	 
	(iii)	 	which was lawfully in possession of the recipient prior to disclosure as evidenced by
written records and which was not acquired directly or indirectly from the discloser;
or
	 
	(iv)	 	which the recipient is required to disclose under law or under the regulations of any
Governmental entity or agency.
The obligations in this Article 12.5 shall expire on the *** anniversary of the
expiration or termination of this Contract.
	 
	 	 	The obligations in this Article 12.5 shall expire on the *** anniversary of the
expiration or termination of this Contract.

12.6 This Contract may only be amended or extended in writing.

12.7 If individual clauses of this Contract should be or become invalid, then the remainder of the
Contract continues to be valid. In this case, the legally admissible regulation or action that has
the closest financial effect to the invalid clause shall be substituted for the invalid clause.

12.8 This Contract shall be binding upon and inure to the benefit of the Parties hereto and their
respective permitted successors and assigns. This Contract may be assigned and delegated by
Customer to an Affiliate, or in connection with any sale, merger or other business combination
involving all or substantially all of Customer’s assets or capital stock. Except as set forth in
the preceding sentence, neither this Contract nor any other rights or obligations hereunder shall
be assigned or delegated by either Party without the prior written consent of the other Party.

12.9 This Contract and any Sale/Purchase Contracts shall be governed by and construed in accordance
with the laws of ***.

12.10 In the event of any dispute arising out of this Contract or any Sale/Purchase Contract, the
Parties shall first seek to settle the dispute amicably by submitting such dispute to the
respective

13

 

Chief Executive Officers who shall seek an amicable commercial resolution to such dispute. In the
event however that such dispute cannot be settled in such a way within *** calendar *** of the
dispute being brought to the attention of the respective CEO’s then the Parties shall submit such
dispute to the courts as set out in Section 12.11 below.

12.11 Each of the Parties hereby submits to the exclusive jurisdiction of the Court of *** for the
determination of any question or dispute arising under or in connection with the Contract or any
Sale/Purchase Contract.

12.12 This Contract, including the Appendices attached hereto constitute the entire understanding
and agreement of the Parties, and shall supersede any prior written or oral agreement or
understanding between the Parties, including without limitation general terms and conditions of
sale of Supplier. In the event of conflict between the provisions of this Contract and/or any of
its Appendixes or any Sale/Purchase Contract the following hierarchy shall apply: (1), this
Contract, (2) the Specifications, (3) the other Appendixes hereto and (4) the Sale/Purchase
Contract.

12.13 Supplier hereby agrees that the Specifications as well as all the Confidential Information
provided by the Customer to the Supplier regarding the Contracted Product are the exclusive
property of Customer and cannot be disclosed to any third Party without prior written consent of
Customer unless otherwise required by law and, in that case, only after giving Customer reasonable
notice and a reasonable opportunity to move or petition the authority requiring such disclosure to
implement measures to protect the Confidential Information.

12.14 The relationship between Customer, on the one hand, and Supplier, on the other hand, is that
of independent contractors and nothing herein shall be deemed to constitute or create the
relationship of partners, joint ventures nor of principal and agent between Customer and Supplier.
Neither Party shall have any express or implied right or authority to assume or create any
obligations on behalf of or in the name of the other Party or to bind the other Party to any
contract, agreement or undertaking with any third party.

12.15 All communications information and notices required to be given under this Contract shall be
sent by registered mail (return receipt requested), or delivered by hand to a duly authorised
representative of the addressee. Such communications information and notices can also be sent by
telefax (but in this case they must be confirmed by subsequent registered mail, return receipt
requested). Such communication information and notices shall be sent to the following addresses,
(or at such other address as either Party may notify to the other in the manner set forth in this
Clause 12.15):

	 	(a)	 	if to Supplier:

Nordmark Arzneimittel GmbH & Co. KG

Pinnauallee 4

25436 Uetersen

Germany

Attention: Dr. Peter Tonne

Fax: 0049 4122 712 510
	 
	 	(b)	 	if to Customer:

Eurand S.p.A.

Via Martin Luther King, 13

20060 Pessano con Bornago (MI)

Italy

14

 

	 	 	 	Attention: Gearoid Faherty

Fax: 0039 02 95745018

IN WITNESS WHEREOF, the Parties have caused this Contract to be executed by their duly authorized
representatives as of the day and year first above written.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Franz Empl 	 	 	 	By:	 	/s/ Jörn Tonne	 	By:	 	/s/ Gearoid Faherty 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	Name: Mr. Franz Empl 	 	 	 	 	 	Name: Dr. Jörn Tonne	 	 	 	Name: Gearoid Faherty	 	 
	 
	 	Title: Chief Financial Officer	 	 	 	 	 	Title: Vice President Marketing and Sales	 	 	 	Title: Chief Executive Officer	 	 
	 
	 	Date: January 3, 2006	 	 	 	 	 	 	 	 	 	Date:  January 3, 2006	 	 

1

 

APPENDIX 1 — SPECIFICATIONS OF THE CONTRACTED PRODUCT

* * *

 

 

APPENDIX 2 — DETERMINATION OF THE PRICES

* * *

 

 

APPENDIX 3 — LEAD TIME

* * *

 

 

APPENDIX 4 — QUALITY AGREEMENT

* * *

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00162-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00162-of-00352.parquet"}]]